Latest News Archive

Please select Category, Year, and then Month to display items
Previous Archive
03 May 2019 | Story Ruan Bruwer | Photo Zimbio
Simoné Gouws
Simoné Gouws (right) in action for the Protea hockey team last year. The defender will be a key player for the Kovsie team in the Varsity hockey competition.

The coach of the first women’s hockey team of the University of the Free State is confident that they can do well in the upcoming Varsity hockey tournament.

The competition works on a gender-rotation system every year. This will be the fourth term of Varsity hockey for women. The Kovsie women has a good record. In 2013 they ended fourth, in 2015 they were second, and in 2017 fifth.

The Kovsies will be facing the University of Johannesburg (UJ) on Friday 3 May 2019. On Saturday, the Maties is lying in wait and the North-West University on Sunday.

“I am confident that we will be doing well. If each player plays her role very well, we should reach the semi-final stage. We have put in the hard work, with good progress. We have played three matches so far in 2019 and haven’t been on the losing side yet,” said Luke Makeleni, head coach.

In friendlies last month, the Kovsies drew to NWU (0-0), defeated UJ by 3-1, and had a good win (6-0) against the Johannesburg club, Shumbas.

“We have quite an experienced squad, with seven survivors from the previous Varsity hockey competition (in 2017), so they know what is expected,” Makeleni said. He is in his third year of coaching the women.

The Kovsies have several players with national experience. Simoné Gouws made her debut for the Proteas last year. Casey-Jean Botha, Shindré-Lee Simmons, Antonet Louw, and Lizanne Jacobs have all represented the South African U21 team. Botha is also in the Protea squad. 

■ The Kovsie team: Wiané Grobler, Chane Hartel, Mikayla Claassen, Anke Badenhorst, Casey-Jean Botha, Shindré-Lee Simmons, Esté van Schalkwyk, Nadia van Staden, Antonet Louw, Michelle Ngoetjane, Heraldine Olin, Lizanne Jacobs, Refilwe Ralikontsane, Mielanka van Schalkwyk, Nela Mbedu, Simoné Gouws, Frances Louw, Kia-Leigh Erasmus.

News Archive

Heart-valve studies receive international recognition
2017-07-11

 Description: Heart-valve studies  Tags: Heart-valve studies  

Prof Francis Smit, Head of the Department of
Cardiothoracic Surgery at the UFS, and Manager of the
Robert WM Frater Cardiovascular Research Centre, with
Kyle Davis, Mechanical Engineer at the centre.

Photo: Rulanzen Martin

Three heart-valve studies which have been developed at the Robert WM Frater Cardiovascular Research Centre at the School of Medicine at the University of the Free State (UFS) were recently presented in Monte Carlo at the conference of the prestigious global Heart Valve Society (HVS).

These studies are all headed by Prof Francis Smit, Head of the Department of Cardiothoracic Surgery at the UFS, and Manager of the Robert WM Frater Cardiovascular Research Centre.
Prof Smit says the HVS is a combination of the former heart-valve societies of Europe and the US. “Studies on heart-valve disease, heart-valve-related products and operations, as well as the design and development of new valves were presented. There are both clinical and development divisions.

He says the study in which the hemodynamics of their redesigned mechanical poppet valve was compared to a commercial bi-leaflet mechanical heart valve, was named as the best poster presentation in the experimental valve development and numerical flow dynamics division. The study, which was presented by Kyle Davis, mechanical engineer at the centre, competed against some of the best heart-valve research units in the world.

The redesigned valve, based on the 1960s Cape Town poppet valve, has the potential to provide a low-cost solution for mechanical heart-valve replacement. It is possible to produce the titanium ring with 3-D printers and is, together with the silicon poppet valve, extremely inexpensive compared to current mechanical valve-manufacturing processes.
The advantages of this valve over current mechanical valves is that, due to the effective and laminar flow characteristics, as well as the simple locking mechanisms, there is a reduced chance of valve thrombosis, and the need for anti-clotting drugs is therefore limited.

It was also confirmed that the new valve more than meets the published FDA (Federal Drug Agency) requirements, which determine the minimum standards of valves for human use in the US.

The redesigned valve also has a very low platelet activation impact, which is responsible for platelet thrombosis and leads to valve thrombosis or strokes. This valve is another heart-valve project by the centre, which is also in the process of evaluating a tri-leaflet polyurethane valve developed by them.


We use cookies to make interactions with our websites and services easy and meaningful. To better understand how they are used, read more about the UFS cookie policy. By continuing to use this site you are giving us your consent to do this.

Accept